APP and Alzheimer disease: These findings highlight that the RAGE-dependent signaling pathway regulates β- and γ-secretase cleavage of APP to produce Aβ, and that RAGE represents a potential therapeutic target for limiting abnormal APP-Aβ metabolism and preventing AD progression [8].